NDS-ECNW has obtained a U.S. patent for its Trimoxi injectable formulation for prophylaxis after cataract surgery, according to a press release.
“Our core formula is highly tunable with any ophthalmic NSAID, with almost all classes of topical antibiotics, including well-known fourth-generation fluoroquinolone, and the varying strength corticosteroids like prednisolone, difluprednate and triamcinolone,” Scott Karolchyk, MSc, executive vice president and chief formulation pharmacist at NDS-ECNW, said in the release.
NDS-ECNW plans to submit its Trimoxi formulation for FDA approval